ISSN 2149-2263 | E-ISSN 2149-2271 Home      
 
Volume : 24 Issue : 2
Current Issue Archive Popular Article Ahead of Print

 
Twelve-month clinical outcomes of sirolimus-eluting stent in coronary artery disease: an experience in real-world Indian patients [Anatol J Cardiol]
Anatol J Cardiol. Ahead of Print: AJC-98452 | DOI: 10.14744/AnatolJCardiol.2020.98452  

Twelve-month clinical outcomes of sirolimus-eluting stent in coronary artery disease: an experience in real-world Indian patients

Srikanth Nathani1, Asif Raheem2, Harish Sanadhya3, Prakash Chandra Purohit3, Ramesh Patel3, Praveen K Alane4, Deepeshkumar Agarwal5, Ramanand Sinha5
1Department of Cardiology, Guntur Medical College, Guntur, Andhra Pradesh-522001, India
2Department of Cardiology, Divine Heart & Research Hospital, Bharuch, Gujarat-392001, India
3Department of Cardiology, Geetanjali Medical College & Hospitals, Udaipur, Rajasthan-313002, India
4Department of Cardiology, Mamata General Hospital, Khammam, Telangana-507002, India
5Department of Cardiology, Mahatma Gandhi Medical College & Hospital, Jaipur, Rajasthan-302022, India

Background: Supraflex (Sahajanand Medical Technologies Pvt. Ltd, Surat, India) is a latest generation biodegradable polymer-coated sirolimus-eluting coronary stent designed on ultra-thin (60µm) cobalt-chromium platform with flexible ‘S-link’. Present study was designed to establish the safety and clinical performance of Supraflex in real-world Indian patients with coronary artery disease.
Methods: The study included total 839 consecutive patients with coronary artery disease, in whom Supraflex was implanted from January, 2014 to August, 2017 at six different tertiary care centres in India. Follow-up was received at 30 days, 6 months and 12 months after index procedure. The primary endpoint of the study was the incidence of major adverse cardiac events (MACE), a composite of cardiac death, myocardial infarction (MI), and target lesion revascularisation (TLR) at 12 months follow-up. The occurrence of stent thrombosis was analysed as safety endpoint.
Results: Total 1025 lesions were treated by implantation of 1098 Supraflex stents. At 12-month follow-up, 4.92% MACE was observed which included 7 (0.86%) cardiac deaths, 16 (1.97%) MI, and 17 (2.09%) TLR. There were only three incidences of stent thrombosis at 12 month follow-up.
Conclusion: The results of this study depicted excellent safety and clinical effectiveness of Supraflex in a high proportion of high risk real-world Indian patient with coronary artery disease.

Keywords: Coronary artery disease, drug-eluting stents, percutaneous coronary intervention, sirolimus, stent thrombosis




Corresponding Author: Srikanth Nathani, India


TOOLS
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share
Send email to author

Similar articles
PubMed
Google Scholar




 
 
KARE Publishing | Copyright © 2019 Turkish Society of Cardiology